What is CRISPR Therapeutics's cash ratio?

CRISPR Therapeutics (CRSP) reported cash ratio of 3.1× in Q1 2026.

How has CRISPR Therapeutics's cash ratio changed year-over-year?

CRISPR Therapeutics's cash ratio increased by 57.8% year-over-year, from 2× to 3.1×.

What is the long-term trend for CRISPR Therapeutics's cash ratio?

Over 5 years (2020 to 2025), CRISPR Therapeutics's cash ratio has grown at a -28.4% compound annual growth rate (CAGR), from 12.4× to 2.3×.

What does cash ratio mean?

Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.

CRISPR Therapeutics CRSP Cash ratio

Cash ratio at other companies

CG OncologyCGON

1×-0.9×

Cogent Biosciences, Inc.COGT

4.2×+1.6×

Arrowhead ResearchARWR

0.6×-0.2×

BridgeBio PharmaBBIO

1.1×-2.5×

Krystal Biotech, Inc.KRYS

4.7×+0.8×

Spyre Therapeutics, Inc.SYRE

1.1×+0.5×

Other financials

Income statement

See full

Revenue$1.5M+68.6%

Operating income-$130.2M+12.2%

Net income-$122.9M+9.6%

EPS (diluted)-$1.28+19.0%

Balance sheet

See full

Cash & equivalents$423.3M+80.0%

Total debt$787.6M+259%

Total equity$1.8B-0.8%

Total assets$2.7B+25.8%

Cash flow

See full

Operating cash flow-$108.9M-102%

CapEx$504.0K+145%

Free cash flow-$109.4M-102%

Valuation

See full

Market cap$5.33B+56.4%

Enterprise value$5.69B+69.8%

P/S1,298.3×+1,208×

Profitability

See full

Operating margin-15,754.2%-17,253pp

Net margin-13,856.5%-15,058pp

FCF margin-9,777.6%-10,759pp

Returns & leverage

See full

Return on equity-31.2%+43.7pp

Debt / equity0.4×+0.3×

Current ratio18×+2.3×

Where this comes from

Calculated from CRISPR Therapeutics’s reported figures.

cash and equivalents/total current liabilities=3.1×

Based on the most recent quarter.

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CRISPR Therapeutics's cash ratio?: CRISPR Therapeutics (CRSP) reported cash ratio of 3.1× in Q1 2026.
How has CRISPR Therapeutics's cash ratio changed year-over-year?: CRISPR Therapeutics's cash ratio increased by 57.8% year-over-year, from 2× to 3.1×.
What is the long-term trend for CRISPR Therapeutics's cash ratio?: Over 5 years (2020 to 2025), CRISPR Therapeutics's cash ratio has grown at a -28.4% compound annual growth rate (CAGR), from 12.4× to 2.3×.
What does cash ratio mean?: Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.